Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Economic Burden of Hospitalizations for Patients with Newly Diagnosed Acute Myeloid Leukemia in Remission in the United States: Retrospective Analysis of an Administrative Claims Database

Clara Chen, Eros Papademetriou, Zephirin Kiendrebeogo, Ravi Potluri

Blood (2021) 138 (Supplement 1): 4976.

https://doi.org/10.1182/blood-2021-147909

Published: 2021

Journal Articles

The Impact of COVID-19 on Acute Myeloid Leukemia (AML) Treatment Patterns in the United States: Retrospective Analysis of an Electronic Medical Records (EMR) Database

Clara Chen, David Rotter, Zephirin Kiendrebeogo, Ravi Potluri

Blood (2021) 138 (Supplement 1): 4139.

https://doi.org/10.1182/blood-2021-147979

Published: 2021

Journal Articles

Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States

Amer M. Zeidan, Daniel A. Pollyea, Uma Borate, Alberto Vasconcelos, Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Lona Gaugler, Gaetano Bonifacio, Clara Chen

Blood (2021) 138 (Supplement 1): 277.

https://doi.org/10.1182/blood-2021-147926

Published: 2021

Journal Articles

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Courtney D. DiNardo, Hartmut Dohner, Amer M. Zeidan, Andre C. Schuh, Paresh Vyas, Eytan M. Stein, Andrew H. Wei, Stephane de Botton, Clara Chen, Jennifer Lord-Bessen, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Shien Guo, Ling Shi, Pau Montesinos

Blood (2021) 138 (Supplement 1): 1244.

https://doi.org/10.1182/blood-2021-147601

Published: 2021

Journal Articles

Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy

Clara Chen, Gerwin A. Huls, Heather Cameron, Beatrice Suero, Alberto Vasconcelos, Lona Gaugler, C.L. Beach

Blood (2021) 138 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2021-148049

Published: 2021

Journal Articles

Impact of Post-Remission Maintenance Therapy (MT) on Outcomes in Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) in Real-World Practice

Ravi Potluri, David Rotter, Zephirin Kiendrebeogo, Clara Chen

Blood (2021) 138 (Supplement 1): 4140.

https://doi.org/10.1182/blood-2021-148044

Published: 2021

Journal Articles

Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment

Tommi Tervonen, Katelyn Cutts, Jaein Seo, Salem Abi Nehme, Ignazia La Torre, Thibaud Prawitz, Clara Chen, CL Beach, Jenny Wang

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136335

Published: 2020

Journal Articles

Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)

Clara Chen, Tim Disher, Muhaimen Siddiqui, Ignazia La Torre, Barry Skikne, MD, Beatrice Suero, Heather Cameron, Roya Gavanji, Chris Cameron

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-136625

Published: 2020

Journal Articles

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP, Thorsten Braun, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137562

Published: 2020

Journal Articles

Indirect Costs of Oral Versus Non-Oral Therapies in Hematologic Malignancies: A Systematic Literature Review

Mir Sohail Fazeli, MDPhD, Divya Pushkarna, Ana Howarth, Margaret Hux, Mir-Masoud Pourrahmat, Clara Chen

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136773

Published: 2020

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

David Cella, PhD, Jan McKendrick, Harrison Davis, Ravi Vij, MBBS, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2190.

https://doi.org/10.1182/blood-2019-122668

Published: 2019

Journal Articles

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Jakub Svoboda, MD, Philippe Armand, MD PhD, Fiona Taylor, Xiaowu Sun, Alejandro Moreno-Koehler, Srikanth Gajavelli, MD, Derek Peterson, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2192.

https://doi.org/10.1182/blood-2019-123980

Published: 2019

Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo

Blood (2019) 134 (Supplement_1): 3480.

https://doi.org/10.1182/blood-2019-122232

Published: 2019

Journal Articles

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Stuart L. Goldberg, MD, Michael J. Mauro, MD

Blood (2019) 134 (Supplement_1): 2929.

https://doi.org/10.1182/blood-2019-127959

Published: 2019

Journal Articles

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Philippe Armand, MD PhD, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, MD, Greta Lozano-Ortega, MSc

Blood (2019) 134 (Supplement_1): 4761.

https://doi.org/10.1182/blood-2019-122302

Published: 2019

Journal Articles

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Stuart L. Goldberg, MD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Scott Justin Keating, MSc, BSc, Hitesh Bhandari, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 4151.

https://doi.org/10.1182/blood-2019-128290

Published: 2019

Journal Articles

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Ravi Vij, MBBS, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Catherine Davis, PharmD, David J. Kuter, MD

Blood (2018) 132 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2018-99-112074

Published: 2018

Journal Articles

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Gordon Cook, David Cella, PhD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Brian GM Durie, MD, Hartmut Goldschmidt, MD, David J. Kuter, MD, Philippe Moreau, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2018-99-112081

Published: 2018

Journal Articles

Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice

Michael J. Mauro, MD, Clara Chen, PhD BS, MS, Jorge E. Cortes, MD, Carlo Gambacorti-Passerini, MD, Ginny P Sen, MPH, Srikanth Gajavelli, MD, Catherine Davis, Mauricette Michallet, MD PhD

Blood (2018) 132 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2018-99-115903

Published: 2018

Journal Articles

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Greta Lozano-Ortega, MSc, Basia Rogula, Karissa Johnston, Julie Villeneuve, Andriy Moshyk, Heather O'Brien, Clara Chen, PhD BS, MS, Joseph M. Connors, MD

Blood (2018) 132 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2018-99-111278

Published: 2018

NARROW

Economic Burden of Hospitalizations for Patients with Newly Diagnosed Acute Myeloid Leukemia in Remission in the United States: Retrospective Analysis of an Administrative Claims Database

The Impact of COVID-19 on Acute Myeloid Leukemia (AML) Treatment Patterns in the United States: Retrospective Analysis of an Electronic Medical Records (EMR) Database

Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Matching Adjusted Indirect Comparison (MAIC) of Oral Azacitidine (Oral-AZA) Versus Injectable AZA in Patients (pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy

Impact of Post-Remission Maintenance Therapy (MT) on Outcomes in Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) in Real-World Practice

Patient Preferences for Maintenance Treatment of Acute Myeloid Leukemia: Results of a Discrete Choice Experiment

Comparative Efficacy of CC-486 Versus Injectable Azacitidine (AZA) in Patients (Pts) with Acute Myeloid Leukemia (AML) in First Remission after Intensive Induction Chemotherapy: Findings from an Indirect Treatment Comparison (ITC)

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Indirect Costs of Oral Versus Non-Oral Therapies in Hematologic Malignancies: A Systematic Literature Review

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only